Sept. 3, 2009--Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the most common form of the disease in adults.
The details can be read here.
No comments:
Post a Comment